A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Clinical trial NCT05824975 · RECRUITING

Trial details

NCT number: NCT05824975
Sponsor: GI Innovation, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor Metastatic Solid Tumor Soft Tissue Sarcoma (STS)Platinum-resistant Ovarian Cancer (PROC)Hepatocellular Carcinoma (HCC)Colorectal Cancer (CRC)HER2 Negative Breast Cancer Cutaneous Melanoma Renal Cell Carcinoma (RCC)

Start date: 2023-05-30
Primary completion: 2025-11-12
Enrollment: 358

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.